Company news: Gilead, Pfizer and Wolters Kluwer

Share this article:

Two potential blockbusters in the pharma pipeline took another step toward reaching market. US regulatory authorities assigned August 2012 PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib. Quad is a single-tablet HIV regimen containing four agents, while tofacitinib is set to become the first oral rheumatoid arthritis drug to enter the injectable RA space. NDAs for both drugs had been submitted earlier this year.

Wolters Kluwer said it completed the sale of its pharma-related marketing & publishing services business to Springer Science+Business Media. The sale, announced in November, is part of Wolters Kluwer's strategy to focus on core health markets through its Wolters Kluwer Health & Pharma Solutions division.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.